Real-world, 52-week Prospective Study to Capture the Reasons for Switch to Triple Combination Therapy, Assess the Clinical and Patient Reported Outcomes in Adults With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Treated With Trixeo Aerosphere™ in Routine Care Settings in Greece

NCT05915182 · clinicaltrials.gov ↗

COMPLETED

Status

212

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Disease, Chronic Obstructive (COPD)

Interventions

COMBINATION_PRODUCT: Budesonide Glycopyrronium bromide Formoterol fumarate pressurized Metered Dose Inhaler

Sponsor

AstraZeneca